Logo

Biosplice Therapeutics: Troy Cox, Karen McGinnis

Apr 20, 2021

Troy Cox and Karen McGinnis have joined the board of directors of Biosplice Therapeutics.

Cox is the former CEO of Foundation Medicine. Prior to that, he was senior VP and an officer at Genentech, and before that, he was president of UCB BioPharmaceuticals, senior VP of Sanofi-Aventis, and held several roles at Schering-Plough.

McGinnis most recently served as VP and chief accounting officer at Illumina. Before that, she was director, president, and CEO of Mad Catz Interactive.

Breaking News
The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.